1INTRODUCTIONPatients with ischemic cardiomyopathy are at risk of scar‐related ventricular arrhythmias. Implanted cardioverter defibrillators (ICDs) reduce mortality by delivering pacing or shock therapies, but these therapies to reduce ventricular arrhythmias may reduce quality of life. The VANISH trial compared strategies of escalated antiarrhythmic drug (AAD) therapy with catheter ablation in patients with ischemic cardiomyopathy and ventricular tachycardia (VT) despite first‐line AAD therapy. It demonstrated a reduction in the composite outcome of death, VT, or appropriate ICD shock in the ablation group. We aimed to compare health‐related quality of life (HRQoL) in patients randomized to escalated therapy and those randomized to ablation in the VANISH trial. We hypothesized that ablation would improve HRQoL by reducing anxiety related to anticipation of arrhythmia symptoms or recurrent ICD shocks.2METHODS2.1VANISH trialThe methods, inclusion and exclusion criteria of the VANISH trial, have been previously published. Briefly, VANISH was a multicenter, randomized trial at 22 ablation centers in Canada, Europe, the United States, and Australia. Eligible patients had a history of myocardial infarction, ICD implant, and recent monomorphic VT treated with amiodarone or a class I or III AAD. Patients were randomized to catheter ablation for VT, or an escalation in AAD therapy. In the escalated
Journal of Cardiovascular Electrophysiology – Wiley
Published: Jan 1, 2018
Keywords: ; ; ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera